Labour induction with an intermediate-dose oxytocin regimen has advantages over a high-dose regimen

被引:6
|
作者
Manjula, B. G. [1 ]
Bagga, R. [1 ]
Kalra, J. [1 ]
Dutta, S. [2 ]
机构
[1] Post Grad Inst Med Educ & Res, Dept Obstet & Gynaecol, Chandigarh 160012, India
[2] Post Grad Inst Med Educ & Res, Dept Neonatol, Chandigarh 160012, India
关键词
Induction; intermediate-dose; labour; oxytocin; NEONATAL HYPERBILIRUBINEMIA; MISOPROSTOL; RECEPTOR; WOMEN;
D O I
10.3109/01443615.2014.968103
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
A total of 200 women planned for labour induction were randomised to receive high-dose oxytocin (6 mU/min with similar increments every 45 min) or intermediate-dose oxytocin (3 mU/min with similar increments every 45 min). Oxytocin solution was prepared with 30 units in 500 ml saline with which the infusion rate in ml/h is numerically equal to oxytocin in mU/min. We observed that the caesarean rate (18% vs 6%, p = 0.009), contraction abnormalities (35% vs 14%, p = 0.0005) and neonatal bilirubin levels (7.99 +/- 2.70 vs 6.80 +/- 2.65, p = 0.002) were higher with high-dose than with intermediate-dose. The induction-delivery interval (IDI) was similar (10 h 13 min with high-dose and 11 h 5 min with intermediatedose; p = 0.237, NS). Nulliparous women benefited more with intermediate-dose as the caesarean rate was higher with high-dose (24.6% vs 7.9%, p = 0.011). Although the caesarean rate was higher in multiparous women with high-dose oxytocin, it was statistically not significant (5.7% vs 2.7%; p = 0.609). Oxytocin regimens for labour induction are usually high-dose (4-6 mU/min) or low-dose (1-1.5 mU/min). The former is associated with more contraction abnormalities and the latter with prolonged IDI; both result in an increased caesarean rate. In order to off set these disadvantages, an intermediate-dose regimen was selected. The increment interval of 45 min was selected in accordance with the pharmacokinetics of oxytocin. We observed a lower caesarean rate when compared with the high-dose regimen, without any increase in the IDI. Hence, we propose that the intermediate-dose oxytocin regimen should be preferred to the high-dose regimen for labour induction.
引用
收藏
页码:362 / 367
页数:6
相关论文
共 50 条
  • [41] A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma
    Taoka, Kennichi
    Okoshi, Yasushi
    Sakamoto, Noriaki
    Takano, Shingo
    Matsumura, Akira
    Hasegawa, Yuichi
    Chiba, Shigeru
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (04) : 617 - 623
  • [42] A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma
    Kennichi Taoka
    Yasushi Okoshi
    Noriaki Sakamoto
    Shingo Takano
    Akira Matsumura
    Yuichi Hasegawa
    Shigeru Chiba
    International Journal of Hematology, 2010, 92 : 617 - 623
  • [43] Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation
    Maschan, AA
    Kryzanovskii, OI
    Yourlova, MI
    Skorobogatova, EV
    Pashanov, ED
    Potapova, YE
    Timonova, LA
    Bogatcheva, NY
    Samochatova, EV
    Roumjantzev, AG
    BONE MARROW TRANSPLANTATION, 1997, 19 (04) : 385 - 387
  • [44] INTERMEDIATE-DOSE CYTOSINE-ARABINOSIDE AND AMSACRINE - AN EFFECTIVE REGIMEN WITH LOW TOXICITY IN REFRACTORY ACUTE NONLYMPHOCYTIC LEUKEMIA
    DEKKER, AW
    NIEUWENHUIS, HK
    VERDONCK, LF
    CANCER, 1990, 65 (09) : 1891 - 1894
  • [45] MITOXANTRONE, ETOPOSIDE, AND INTERMEDIATE-DOSE CYTARABINE - AN EFFECTIVE AND TOLERABLE REGIMEN FOR THE TREATMENT OF REFRACTORY ACUTE MYELOID-LEUKEMIA
    AMADORI, S
    ARCESE, W
    ISACCHI, G
    MELONI, G
    PETTI, MC
    MONARCA, B
    TESTI, AM
    MANDELLI, F
    JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) : 1210 - 1214
  • [46] Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation
    AA Maschan
    OI Kryzanovskii
    MI Yourlova
    EV Skorobogatova
    ED Pashanov
    YE Potapova
    LA Timonova
    NY Bogatcheva
    EV Samochatova
    AG Roumjantzev
    Bone Marrow Transplantation, 1997, 19 : 385 - 387
  • [47] FEASIBILITY ON SHORT HYDRATION REGIMEN OF INTERMEDIATE-TO HIGH-DOSE CISPLATIN-BASED CHEMOTHERAPY FOR OUTPATIENT TREATMENT
    Sakaida, E.
    Ashinuma, H.
    Kitazono, S.
    Kitazono, M.
    Kitamura, A.
    Ohoka, Y.
    Uehara, T.
    Oku, T.
    Imai, C.
    Saeki, H.
    Nakasa, H.
    Kitada, M.
    Sekine, I.
    Takiguchi, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 89 - 89
  • [48] Safety and feasibility of outpatient high-dose cytarabine and intermediate-dose cytarabine for consolidation therapy in acute myeloid leukemia
    Li, Wenhui
    Richter, Katherine
    Lee, Jamie
    McCarthy, Kevin
    Kubal, Timothy
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (08) : 1812 - 1818
  • [49] A 'Hybrid' Radiotherapy Regimen Designed for Immunomodulation: Combining High-Dose Radiotherapy with Low-Dose Radiotherapy
    Ji, Hongshan
    Zhou, Zhiguo
    CANCERS, 2022, 14 (14)
  • [50] SHORT DURATION, HIGH-DOSE, ALTERNATING CHEMOTHERAPY IN METASTATIC NEUROBLASTOMA - (ENSG-3C INDUCTION REGIMEN)
    PINKERTON, CR
    ZUCKER, JM
    HARTMANN, O
    PRITCHARD, J
    BROADBENT, V
    MORRISJONES, P
    BREATNACH, F
    CRAFT, AE
    PEARSON, ADJ
    WALLENDSZUS, KR
    PHILIP, T
    BRITISH JOURNAL OF CANCER, 1990, 62 (02) : 319 - 323